Roger J. Packer

50.4k total citations · 7 hit papers
465 papers, 27.6k citations indexed

About

Roger J. Packer is a scholar working on Genetics, Neurology and Molecular Biology. According to data from OpenAlex, Roger J. Packer has authored 465 papers receiving a total of 27.6k indexed citations (citations by other indexed papers that have themselves been cited), including 328 papers in Genetics, 214 papers in Neurology and 121 papers in Molecular Biology. Recurrent topics in Roger J. Packer's work include Glioma Diagnosis and Treatment (324 papers), Neuroblastoma Research and Treatments (142 papers) and Neurofibromatosis and Schwannoma Cases (75 papers). Roger J. Packer is often cited by papers focused on Glioma Diagnosis and Treatment (324 papers), Neuroblastoma Research and Treatments (142 papers) and Neurofibromatosis and Schwannoma Cases (75 papers). Roger J. Packer collaborates with scholars based in United States, Canada and Switzerland. Roger J. Packer's co-authors include Lucy B. Rorke, Gilbert Vézina, James M. Boyett, Leslie N. Sutton, Leslie L. Robison, Jaclyn A. Biegel, Jeffrey C. Allen, Luis Schut, Tobey J. MacDonald and Robert A. Zimmerman and has published in prestigious journals such as New England Journal of Medicine, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Roger J. Packer

446 papers receiving 27.1k citations

Hit Papers

Phase III Study of Craniospinal Radiation Therapy Followe... 1996 2026 2006 2016 2006 1996 2002 1999 2009 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma
    2006 637 citations Roger J. Packer, Amar Gajjar et al. Journal of Clinical Oncology profile →
  2. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity
    1996 567 citations Lucy B. Rorke, Roger J. Packer et al. profile →
  3. Study design and cohort characteristics of the childhood cancer survivor study: A multi‐institutional collaborative project
    2002 553 citations Roger J. Packer, Malcolm A. Smith et al. profile →
  4. Metastasis Stage, Adjuvant Treatment, and Residual Tumor Are Prognostic Factors for Medulloblastoma in Children: Conclusions From the Children's Cancer Group 921 Randomized Phase III Study
    1999 546 citations James M. Boyett, Jonathan L. Finlay et al. Journal of Clinical Oncology profile →
  5. The Childhood Cancer Survivor Study: A National Cancer Institute–Supported Resource for Outcome and Intervention Research
    2009 506 citations Roger J. Packer et al. Journal of Clinical Oncology profile →
  6. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours
    2022 163 citations Roger J. Packer et al. profile →
  7. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations
    2023 125 citations Éric Bouffet, Uri Tabori et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roger J. Packer United States 91 15.0k 10.1k 8.1k 5.6k 4.9k 465 27.6k
Larry E. Kun United States 77 10.2k 0.7× 5.8k 0.6× 4.7k 0.6× 6.0k 1.1× 4.0k 0.8× 373 20.5k
Amar Gajjar United States 78 13.3k 0.9× 5.6k 0.6× 8.9k 1.1× 4.7k 0.8× 4.2k 0.9× 429 23.5k
Éric Bouffet Canada 69 10.3k 0.7× 5.9k 0.6× 5.0k 0.6× 3.4k 0.6× 2.5k 0.5× 557 17.6k
Lucy B. Rorke United States 78 8.8k 0.6× 5.4k 0.5× 7.7k 0.9× 3.0k 0.5× 2.3k 0.5× 258 20.3k
Thomas E. Merchant United States 71 9.1k 0.6× 3.8k 0.4× 2.7k 0.3× 6.5k 1.2× 3.1k 0.6× 444 17.9k
James M. Boyett United States 70 7.8k 0.5× 4.2k 0.4× 4.4k 0.5× 2.9k 0.5× 2.8k 0.6× 232 15.2k
Jonathan L. Finlay United States 63 9.0k 0.6× 5.0k 0.5× 4.2k 0.5× 3.2k 0.6× 1.2k 0.2× 326 13.6k
Carol Kruchko United States 47 16.4k 1.1× 5.6k 0.6× 8.3k 1.0× 5.9k 1.1× 865 0.2× 139 29.3k
Henry S. Friedman United States 95 21.5k 1.4× 5.9k 0.6× 15.0k 1.8× 7.9k 1.4× 1.0k 0.2× 567 38.4k
Ian F. Pollack United States 71 7.9k 0.5× 4.6k 0.5× 5.1k 0.6× 2.2k 0.4× 1.0k 0.2× 381 16.6k

Countries citing papers authored by Roger J. Packer

Since Specialization
Citations

This map shows the geographic impact of Roger J. Packer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger J. Packer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger J. Packer more than expected).

Fields of papers citing papers by Roger J. Packer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger J. Packer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger J. Packer. The network helps show where Roger J. Packer may publish in the future.

Co-authorship network of co-authors of Roger J. Packer

This figure shows the co-authorship network connecting the top 25 collaborators of Roger J. Packer. A scholar is included among the top collaborators of Roger J. Packer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger J. Packer. Roger J. Packer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kilburn, Lindsay, Adriana Fonseca, Roger J. Packer, et al.. (2024). MR-guided focused ultrasound in pediatric neurosurgery: current insights, technical challenges, and lessons learned from 45 treatments at Children’s National Hospital. Neurosurgical FOCUS. 57(3). E6–E6. 5 indexed citations
3.
Roth, Holger R., Syed Muhammad Anwar, Erin R. Bonner, et al.. (2024). Early prognostication of overall survival for pediatric diffuse midline gliomas using MRI radiomics and machine learning: A two-center study. Neuro-Oncology Advances. 6(1). vdae108–vdae108. 5 indexed citations
4.
5.
6.
Fangusaro, Jason, Robert A. Avery, Michael J. Fisher, et al.. (2024). Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium. Clinical Cancer Research. 30(11). 2303–2308. 4 indexed citations
7.
Plotkin, Scott R., Jeffrey C. Allen, Girish Dhall, et al.. (2023). Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma. Neuro-Oncology. 25(8). 1498–1506. 12 indexed citations
8.
Xu, Zhenhua, Najiba Murad, Daniel Malawsky, et al.. (2022). OLIG2 Is a Determinant for the Relapse of MYC -Amplified Medulloblastoma. Clinical Cancer Research. 28(19). 4278–4291. 6 indexed citations
9.
Ullrich, Nicole J., Sanjay P. Prabhu, Roger J. Packer, et al.. (2020). Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1‐associated optic pathway gliomas in children. Pediatric Blood & Cancer. 68(4). e28833–e28833. 13 indexed citations
10.
Packer, Roger J., Antonio Iavarone, David Jones, et al.. (2020). Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. Neuro-Oncology. 22(6). 773–784. 40 indexed citations
11.
Tao, Ran, Najiba Murad, Zhenhua Xu, et al.. (2019). MYC Drives Group 3 Medulloblastoma through Transformation of Sox2+ Astrocyte Progenitor Cells. Cancer Research. 79(8). 1967–1980. 29 indexed citations
12.
Plotkin, Scott R., Dan G. Duda, Alona Muzikansky, et al.. (2019). Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. Journal of Clinical Oncology. 37(35). 3446–3454. 74 indexed citations
13.
Panditharatna, Eshini, Lindsay Kilburn, Mariam Aboian, et al.. (2018). Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy. Clinical Cancer Research. 24(23). 5850–5859. 123 indexed citations
14.
Khatua, Soumen, David H. Gutmann, & Roger J. Packer. (2017). Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights. Pediatric Blood & Cancer. 65(3). 26 indexed citations
15.
Gajjar, Amar, Clinton F. Stewart, David W. Ellison, et al.. (2013). Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study. Clinical Cancer Research. 19(22). 6305–6312. 164 indexed citations
16.
Jakacki, Regina I., Peter C. Burger, Tianni Zhou, et al.. (2012). Outcome of Children With Metastatic Medulloblastoma Treated With Carboplatin During Craniospinal Radiotherapy: A Children's Oncology Group Phase I/II Study. Journal of Clinical Oncology. 30(21). 2648–2653. 131 indexed citations
17.
Packer, Roger J., Amar Gajjar, Gilbert Vézina, et al.. (2006). Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. Journal of Clinical Oncology. 24(25). 4202–4208. 637 indexed citations breakdown →
18.
Packer, Roger J., Jaclyn A. Biegel, Susan M. Blaney, et al.. (2002). Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System: Report on Workshop. Journal of Pediatric Hematology/Oncology. 24(5). 337–342. 164 indexed citations
19.
Piller, Neil, et al.. (1996). Accepting responsibility for health management: Partner training as an effective means of managing chronic lymphoedema. 29. 266–269. 2 indexed citations
20.
Heideman, Richard L., Andrea Gillespie, Harry Ford, et al.. (1989). Phase I trial and pharmacokinetic evaluation of fazarabine in children.. PubMed. 49(18). 5213–6. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Larry E. Kun Breakdown of academic impact, for papers by Amar Gajjar Breakdown of academic impact, for papers by Éric Bouffet Breakdown of academic impact, for papers by Lucy B. Rorke Breakdown of academic impact, for papers by Thomas E. Merchant Breakdown of academic impact, for papers by James M. Boyett Breakdown of academic impact, for papers by Jonathan L. Finlay Breakdown of academic impact, for papers by Carol Kruchko Breakdown of academic impact, for papers by Henry S. Friedman Breakdown of academic impact, for papers by Ian F. Pollack
Rankless by CCL
2026